secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001193125-25-021348
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium reports itolizumab Phase 2 UC topline: 23.3% clinical remission vs 10% placebo
--------------------------------------------------------------------------------

- Primary endpoint: 23.3% clinical remission at week 12 for itolizumab vs 20.0% adalimumab, 10.0% placebo.
- Secondary: 63.3% clinical response (itolizumab) vs 60.0% adalimumab, 46.7% placebo; endoscopic remission 16.7% each itolizumab/adalimumab vs 6.7% placebo.
- Baseline imbalance: 23% of itolizumab arm had severe disease (Mayo=11) vs 0% placebo/adalimumab; 66% left-sided colitis vs 30%/43%.
- Itolizumab was generally well tolerated with no new safety signal; 90 patients randomized 1:1:1 in India.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/0001193125-25-021348-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312525021348/d898732d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-021348

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer